173 related articles for article (PubMed ID: 36234743)
21. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
[No Abstract] [Full Text] [Related]
22. Theoretical studies on the selectivity mechanisms of PI3Kδ inhibition with marketed idelalisib and its derivatives by 3D-QSAR, molecular docking, and molecular dynamics simulation.
Zhu J; Ke K; Xu L; Jin J
J Mol Model; 2019 Jul; 25(8):242. PubMed ID: 31338599
[TBL] [Abstract][Full Text] [Related]
23. Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies.
Zhu J; Hou T; Mao X
Drug Discov Today; 2015 Aug; 20(8):988-94. PubMed ID: 25857437
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3Kδ inhibitors.
Feng Y; Duan W; Fan S; Zhang H; Zhang SQ; Xin M
Bioorg Med Chem; 2019 Oct; 27(19):115035. PubMed ID: 31434616
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and biological evaluation of novel selective PI3Kδ inhibitors containing pyridopyrimidine scaffold.
Ma M; Feng Y; Zhang SQ; Duan W; Gao L; Yuan B; Xin M
Future Med Chem; 2023 Aug; 15(16):1491-1509. PubMed ID: 37565336
[No Abstract] [Full Text] [Related]
26. Identification of a potent and selective phosphatidylinositol 3-kinase δ inhibitor for the treatment of non-Hodgkin's lymphoma.
Zuo WQ; Hu R; Wang WL; Zhu YX; Xu Y; Yu LT; Liu ZH; Wang NY
Bioorg Chem; 2020 Dec; 105():104344. PubMed ID: 33091667
[TBL] [Abstract][Full Text] [Related]
27. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
[TBL] [Abstract][Full Text] [Related]
28. Targeting PI3Kδ: emerging therapy for chronic lymphocytic leukemia and beyond.
Wei M; Wang X; Song Z; Jiao M; Ding J; Meng LH; Zhang A
Med Res Rev; 2015 Jul; 35(4):720-52. PubMed ID: 25763934
[TBL] [Abstract][Full Text] [Related]
29. Discovery of a Potent and Selective PI3Kδ Inhibitor (
Shukla MR; Patra S; Verma M; Sadasivam G; Jana N; Mahangare SJ; Vidhate P; Lagad D; Tarage A; Cheemala M; Kulkarni C; Bhagwat S; Chaudhari VD; Sayyed M; Pachpute V; Phadtare R; Gole G; Phukan S; Sunkara B; Samant C; Shingare M; Naik A; Trivedi S; Marisetti AK; Reddy M; Gholve M; Mahajan N; Sabde S; Patil V; Modi D; Mehta M; Nigade P; Tamane K; Tota S; Goyal H; Volam H; Pawar S; Ahirrao P; Dinchhana L; Mallurwar S; Akarte A; Bokare A; Kanhere R; Reddy N; Koul S; Dandekar M; Singh M; Bernstein PR; Narasimham L; Bhonde M; Gundu J; Goel R; Kulkarni S; Sharma S; Kamboj RK; Palle VP
J Med Chem; 2020 Dec; 63(23):14700-14723. PubMed ID: 33297683
[TBL] [Abstract][Full Text] [Related]
30. PI3Kδ inhibitors for the treatment of cancer: a patent review (2015-present).
Feng Y; Cu X; Xin M
Expert Opin Ther Pat; 2019 Dec; 29(12):925-941. PubMed ID: 31670985
[No Abstract] [Full Text] [Related]
31. Idelalisib.
Zirlik K; Veelken H
Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
[TBL] [Abstract][Full Text] [Related]
32. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase
Shin N; Stubbs M; Koblish H; Yue EW; Soloviev M; Douty B; Wang KH; Wang Q; Gao M; Feldman P; Yang G; Hall L; Hansbury M; O'Connor S; Leffet L; Collins R; Katiyar K; He X; Waeltz P; Collier P; Lu J; Li YL; Li Y; Liu PCC; Burn T; Covington M; Diamond S; Shuey D; Roberts A; Yeleswaram S; Hollis G; Metcalf B; Yao W; Huber R; Combs A; Newton R; Scherle P
J Pharmacol Exp Ther; 2020 Jul; 374(1):211-222. PubMed ID: 32345620
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and in vitro biological evaluation of 2-aminopyridine derivatives as novel PI3Kδ inhibitors for hematological cancer.
Yang C; Gong Y; Gao Y; Deng M; Liu X; Yang Y; Ling Y; Jia Y; Zhou Y
Bioorg Med Chem Lett; 2023 Feb; 82():129152. PubMed ID: 36706844
[TBL] [Abstract][Full Text] [Related]
34. Design and Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3Kδ Inhibitors for the Treatment of B-Cell Malignancies.
Zhang J; Jiang H; Lin S; Wu D; Tian H; Jiang L; Cui Y; Jin J; Chen X; Xu H
J Med Chem; 2022 Jun; 65(11):8011-8028. PubMed ID: 35609190
[TBL] [Abstract][Full Text] [Related]
35. Discovery of novel pyrido[3,2-d]pyrimidine derivatives as selective and potent PI3Kδ inhibitors.
Bai H; Sun J; Lei H; Zhang SQ; Yuan B; Ma M; Xin M
Drug Dev Res; 2023 Dec; 84(8):1709-1723. PubMed ID: 37732677
[TBL] [Abstract][Full Text] [Related]
36. Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.
Liu L; Li X; Cheng Y; Wang L; Yang H; Li J; He S; Shuangjie Wu ; Yin Q; Xiang H
Eur J Med Chem; 2019 Feb; 164():304-316. PubMed ID: 30605829
[TBL] [Abstract][Full Text] [Related]
37. Integrated molecular modeling techniques to reveal selective mechanisms of inhibitors to PI3Kδ with marketed Idelalisib.
Zhu J; Jia L; Jiang Y; Yu Q; Xu L; Cai Y; Chen Y; Li H; Gang H; Liang W; Jin J
Chem Biol Drug Des; 2021 Jun; 97(6):1158-1169. PubMed ID: 33657663
[TBL] [Abstract][Full Text] [Related]
38. Discovery of New Phosphoinositide 3-kinase Delta (PI3Kδ) Inhibitors via Virtual Screening using Crystallography-derived Pharmacophore Modelling and QSAR Analysis.
Al-Sha'er MA; Al-Aqtash RA; Taha MO
Med Chem; 2019; 15(6):588-601. PubMed ID: 30799792
[TBL] [Abstract][Full Text] [Related]
39. Discovery of (
Li F; Liang X; Jiang Z; Wang A; Wang J; Chen C; Wang W; Zou F; Qi Z; Liu Q; Hu Z; Cao J; Wu H; Wang B; Wang L; Liu J; Liu Q
J Med Chem; 2020 Nov; 63(22):13973-13993. PubMed ID: 33180507
[TBL] [Abstract][Full Text] [Related]
40. Discovery of Novel Indazoles as Potent and Selective PI3Kδ Inhibitors with High Efficacy for Treatment of Hepatocellular Carcinoma.
Qi J; Wang W; Tang Y; Lou S; Wang J; Yuan T; He Q; Yang B; Zhu H; Cui S
J Med Chem; 2022 Mar; 65(5):3849-3865. PubMed ID: 35191698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
